Grant: Project Grant

Oral cancer is the 9th most commonly diagnosed cancer worldwide. Its dismal survival rates are largely due to the fact that disease is usually diagnosed at advanced stages and also due to its high rate of post-treatment recurrence. Earlier detection of new or recurrent oral malignancy is essential for better patient outcomes. This is because early detection facilitates intervention at more localized and, thus, more treatable disease stages. We have discovered a biomarker that facilitates early detection of primary and recurrent oral malignancy via a simple blood test. Our objectives for this proposal are to further optimize the detection of this biomarker to facilitate its translation for routine clinical use. Success with this project will produce a clinically-useful and cost-effective blood test for screening people with both new and recurrent oral malignancy, setting the stage for more effective patient management and improved patient outcomes.